EN
WHO Meeting Held to Review the Results of Sinovac SARS Vaccine Phase I Trial and Discuss Phase II Protocols
Geneva -- On June 1 2005 the Initiative for Vaccine Research (IVR), a division of World Health Organization (WHO), organized a conference to review the results of the Phase I SARS vaccine trial and discuss Phase II protocol at WHO headquarters in Geneva . Dr. Marie-Paule Kieny Director of IVR hosted the meeting, which was attended by seven WHO professionals, and representatives from the National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) and Sinovac Biotech Ltd. The NICPBP representatives included Mr. Guanmu Dong, director of NIBPCP, and Mr. Junzhi Wang, deputy general director of NICPBP. Representatives from Sinovac were Ms. Nan Wang, vice president of Sinovac, and Dr. Hong Gao, medical manager of Sinovac.
Dr.Gao gave a presentation about the Phase I clinical trial results of Sinovac’s SARS vaccine, and a draft proposal for conduction Phase II clinical trials. After detailed discussions, the WHO representatives expressed to the general audience, their satisfaction with the results of the phase I trial. The second topic of discussion was on the protocol of Phase II trial. The WHO professionals gave several valuable technical recommendations on Phase II trial.
http://www.nicpbp.org.cn/SHW/nicpbp.nsf/sydocs/E0C8E95D1F7E317F4825701B001408C8?opendocument
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.